Hepatitis/MASH

Over the past 2 years, about 36 cases of acute hepatitis C virus infection were reported at 19 different hemodialysis clinics.

The FDA has approved Merck's elbasvir and grazoprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Researchers seek to predict age-related responses to hepatitis B vaccination.

Patients who do not have HIV and adhere to their prescribed regimens usually have undetectable HCV RNA after 12 weeks of therapy.

Hepatitis C treatment with pegylated interferon alpha may lead to anti-interferon antibodies.

HCV treatment has been shown to cure up to 100% of patients depending on genotype and stage of liver disease.

Global therapeutics market for chronic hepatitis B virus projected to rise from $2.4 billion to $3 billion by 2024.

One-third of HIV-infected Americans are co-infected with hepatitis C virus (HCV), and 75% to 90% of HIV-positive intravenous drug users are co-infected.

Pricing Sovaldi based on the predicted benefits of therapy in specific hepatitis C patient groups could ultimately lead to greater access for patients.

Large geographic disparities exist in the likelihood of either being removed from the transplant list due to progressive disease or actually receiving a transplant.

Pair of daily ribavirin-free oral drugs will be analyzed in patients with hepatitis C genotypes 1-6.

Tenofovir alafenamide is a once-daily treatment for adults with chronic hepatitis B virus infection.

Pair of daily ribavirin-free oral drugs will be analyzed in patients with hepatitis C genotypes 1-6.

Tenofovir alafenamide is a once-daily treatment for adults with chronic hepatitis B virus infection.

Gilead Sciences Inc has submitted a new drug application to the FDA for tenofovir alafenamide, a once-daily treatment for adults with chronic hepatitis B virus infection.

Burdened by the symptoms of hepatitis C, an Australian man faced an uncertain future before new antiviral drugs offered hope.

Burdened by the symptoms of hepatitis C, an Australian man faced an uncertain future before new antiviral drugs offered hope.

The world is a better place as a result of vaccines, but we cannot force patients to receive them.

Research explores non-invasive methods to allow for the safe study of cancer progression.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Process may lead to better quality liver cells derived from clinical grade stem cells.

Unsanitary living conditions promote spread of the virus.

Phase 3 study results show high efficacy and improved renal and bone safety parameters with tenofovir alafenamide regimen.